Merck Partners with Isomorphic Labs to Discover AI-Designed Cancer Drugs
Merck has entered into a strategic research collaboration with Isomorphic Labs to discover new cancer drug candidates using artificial intelligence (AI). The partnership will combine Isomorphic Labs’ AI-powered drug design technology with Merck’s drug discovery expertise and proprietary biological data.
Announced on November 19, 2026, the collaboration will focus on discovering small-molecule drug candidates against an oncology target considered strategically important by Merck.
Under the agreement, Isomorphic Labs will use its proprietary Drug Design Engine (IsoDDE) to predict how potential drug molecules interact with biological targets and generate new molecular designs. The company will also use selected proprietary datasets provided by Merck to support the research.
Merck will be responsible for the next stages of development, including preclinical and clinical research, manufacturing and commercialization of any products that emerge from the collaboration.
The financial terms of the agreement include an upfront payment from Merck to Isomorphic Labs. Isomorphic Labs will also be eligible for additional payments based on research, development, regulatory and commercial milestones, along with tiered royalties on future net sales.
The agreement also gives Isomorphic Labs the option to co-fund development activities in exchange for higher royalty payments.
Isomorphic Labs’ IsoDDE platform uses advanced AI models to help researchers understand biological systems and design potential drug molecules. The technology aims to improve the drug discovery process by predicting how molecules interact with proteins and identifying promising candidates for further research.
Traditional drug discovery can take considerable time and involve testing large numbers of chemical compounds. AI-based platforms may help researchers narrow down potential candidates earlier and make the discovery process more efficient.
George Addona, Senior Vice President and Head of Discovery, Preclinical Development and Translational Medicine at Merck Research Laboratories, said that close coordination between computational research and laboratory experiments is important for successfully applying AI in drug discovery.
He added that combining Merck’s internal data and scientific expertise with Isomorphic Labs’ modelling and computing capabilities could help both companies design better drug candidates faster.
Sarah Skerratt, Chief Research Officer at Isomorphic Labs, said the partnership would allow the company to apply its drug design engine to a challenging research programme and support the development of new treatments for patients with unmet medical needs.
Founded in 2021, Isomorphic Labs is an AI-driven drug discovery company that uses computational biology and machine learning to develop new medicines. The company was established as a spinout from Google DeepMind and is led by CEO Sir Demis Hassabis.
The collaboration adds to Isomorphic Labs’ growing partnerships with major pharmaceutical companies, including Novartis and Eli Lilly.
The latest agreement highlights the increasing role of artificial intelligence in pharmaceutical research. By combining AI-powered molecular design with established drug development capabilities, Merck and Isomorphic Labs aim to identify promising new cancer drug candidates and potentially accelerate the development of future oncology treatments.
